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ture. We assumed re-intervention and septicaemia rates of ecAVG were equivalent 
to standard AVGs. Resource use was based on hospital practice and unit costs from 
published National Health Service datasets. Results: Over a 6 month period, total 
treatment costs per patient were £5,882 in the TCVC strategy and £4,954 in the 
ecAVG strategy, delivering potential savings of £927 per patient. Although ecAVG’s 
had higher procedure and re-intervention costs reflecting longer procedure time 
and device costs (£3,014 vs £1,836), these were offset by significant reductions in 
septicaemia treatment costs (£1,322 vs £2,176) and in-patient waiting time bed costs 
(£619 vs £1,870). ConClusions: Adopting ecAVG’s as an alternative to TCVCs can 
potentially deliver cost savings in this hospital. The two treatment strategies will 
now be assessed in a RCT.
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objeCtives: Budget impact (BIM) analysis of the use of paricalcitol versus standard 
of care (SOC) for the treatment of secondary hyperparathyroidism (SHPT) in chronic 
kidney disease (CKD) considering paricalcitol treatment start in the pre-dialysis 
phase. Methods: Effects and costs deriving from the use of paracalcitol versus 
SOC for treatment of SHPT in CKD patients were simulated using a Markov models 
contemplating the natural history of CKD and introducing the use of parcalcitol 
treatment from the early stage of kidney disease (CKD3) versus SOC considering 
the use of comparator only from the dialysis stage. A 5-years horizon and the Italian 
NHS perspective were used. Epidemiologic and clinical data were derived from 
literature and other assumptions were discussed with clinicians. Both national 
tariffs and costs from literature were used upon availability and referred to 2012. 
One-way sensitivity analyses for model inputs were conducted. Costs and effects 
were discounted at 3% annum. Results: The use of paricalcitol for the treatment 
of SHPT was cost-saving for the Italian NHS even starting therapy in the early stage 
of CKD. In a hypothetical cohort of 1,000 patients per treatment group, the overall 
direct health costs were 10,181,627 Euro for paricalcitol and 10,816,812 Euro for SOC. 
Both drug-related and others direct costs were lower for paricalcitol resulting in 
an overall cost-saving of 1,256 Euro per-patient and stemming from a per-patient 
increase of drug-related costs of 5,126 Euro and a saving of the others direct costs 
of 6,382 Euro. ConClusions: Timing paricalcitol treatment from the early stage 
of CKD could induce a cost-saving for the NHS. Moreover, despite the high acquisi-
tion costs for paricalcitol, benefits resulting from an early treatment of SHPT could 
determine a decrease of the others direct costs exceeding the burden of drug costs.
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bACkgRound: Clinical studies have shown that treatment of chronic kidney dis-
ease patients at predialysis stage (predialysis) with a low protein diet (LPD) and 
ketoanalogues of essential aminoacids (ketoanalogues) provides clinical and eco-
nomic benefits. Then, it’s actual to define pharmacoeconomic effects of using LPD 
and ketoanalogues in predialysis patients in Russian Federation (RF). objeCtives: 
To provide pharmacoeconomic assessment of LPD and ketoanalogues supply of 
predialysis patients in RF. Methods: Decision tree modelling approach, cost-utility 
(CUA) and budget impact analyses (BIA) were performed. Direct costs (ketoana-
logues, erythropoietin, hemodialysis, peritoneal dialysis, etc.) were considered. Two 
patients groups were compared in the model: ketoanalogues and LPD was adminis-
trated for the first arm in predialysis stage, while second arm started in the model of 
dialysis patients. Results of retrospective efficacy analysis state, that administration 
of keto-analogues and LPD delays start of dialysis at least for one year. State utility 
approach was used for cost-utility analysis. Time horizon of the model was up to 5 
years. NHS prices and Sechenov University hospitals price lists were used. Results: 
The first year annual costs were $38511 per patient for the patients group on dialysis 
and $13763 for the group of ketoanalogues. The results of BIA have shown, that total 
cost-saving per patient in the group of ketoanalogues and LPD over 5-year period 
was $21812 compared with the dialysis group. Cost-utility ratio (CUR) for the keto-
analogues and LPD group varies from $15316 per QALY for the first year to $34673 
per QALY over five years, while in the dialysis group CUR ranged from $50051 per 
QALY in the first year to $45819 per QALY over five years. ConClusions: CUA have 
shown that treatment of predialysis patients with ketoanalogues and LPD in RF is a 
preferable technology and provides cost-saving of $21812 over five years per patient.
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objeCtives: Comparing the costs of Darifenacin, Oxybutynin, Propiverine, 
Solifenacin, Tolterodine, and Trospium chloride for the treatment of overactive blad-
der (OAB) and incontinence in patients 40 years of age or older in Germany. dAtA 
And Methods: Costs are assessed from a (public) health insurance perspective. 
The study is based on a unique sickness fund dataset of 2.9 million insured per-
sons which includes records on out- and inpatient care, pharmaceuticals, adjuvant 
therapies, and medical aids for 2009. 21,302 persons aged 40 years or older received 
anticholinergics and were classified as OAB patients. Of these OAB patients, 3,846 
also suffered from incontinence. Multiple linear regression models were performed, 
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objeCtives: Urinary Incontinence (UI) is associated with several chronic health 
conditions including arthritis. Literature suggests that arthritis may modify the 
association between chronic conditions and UI. Little is known about this interaction 
of arthritis with other chronic diseases and their impact on UI. This study exam-
ined these associations. Methods: This was a retrospective case-control study of 
a 10% random sample of IMS Life Link data from 2001-2011. Subjects were > = 18 
years of age and continuously enrolled 18 months pre, and 12 months post their 
first index diagnosis. UI cases had at least two outpatient or one inpatient and one 
outpatient claim at least 7 days apart, or one pharmacy claim for a UI drug. Controls 
without UI had the same eligibility criteria as cases and were matched with cases 
3:1 on age, gender and region. Comorbidities are observed in the 12-month pre-
index period after leaving 6 months buffer time immediately before index diagno-
sis. Conditional logistic regression (CLR) adjusted for health system variables and 
other co-morbidities was used to investigate the effect of the interaction between 
arthritis and other comorbidities on UI. Results: There were 24,499 cases, and 
73,497 controls with a mean age of 58.29 years and 69.8% females. Forty percent of 
cases and 24.8% of controls had arthritis in their pre index period. Arthritis alone 
was significantly associated with UI alone (aOR = 1.87, p< 0.0001), multiple Sclerosis 
(MS) alone (aOR = 4.25, p< 0.0001) and cardiovascular diseases (CVD) alone (aOR = 
1.32, p< 0.0001). However, the interaction of arthritis and MS (aOR = 7.48, p< 0.0001), 
and arthritis and CVD (aOR = 2.10, p< 0.0001) increased considerably the odds of 
developing UI. ConClusions: Compared to arthritis or chronic conditions alone, 
the combination of arthritis with other chronic conditions significantly increases 
the risk of having UI.
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objeCtives: Hyperphosphatemia, an electrolyte disorder characterized by elevated 
levels of phosphate in the blood, is a risk factor for chronic kidney disease (CKD) 
and associated with increased risk of mortality. In addition to dietary changes 
phosphate binders (PB) may be administered to hyperphosphatemia patients to 
reduce phosphate levels. The objective of this study is to evaluate the impact of 
PB on CKD patients with hyperphosphatemia. Methods: A retrospective, cross-
sectional analysis was conducted on 70,728 inpatient discharges in the MedAssets 
health system data diagnosed with CKD and hyperphosphatemia for 2009 through 
2013. Cohorts of patients with and without PB were matched on age, sex, principal 
diagnosis, hospital bed size, region, and teaching status using a propensity score 
and Greedy matching algorithm. In-hospital mortality and length of stay (LOS) were 
compared between cohorts using multivariate logistic and negative binomial regres-
sion models, respectively, controlling for Deyo-Charlson comorbidity score, compli-
cations, and procedures. Results: Of patients diagnosed with hyperphosphatemia 
approximately 46% were administered PB during their stay. Matching resulted in 
11432 patients in each cohort with a mean age of 61 and proportionately more 
males (54%) than females (46%). Patients receiving PB had higher Deyo-Charlson 
scores (5.70 vs. 5.46, p< .0001) and higher rates of end-stage renal disease (74.6% vs 
44.1%, p< .0001) and hemodialysis (65.4% vs 35.4%, p< .0001). Patients without PB had 
higher rates of acute kidney failure (48.0% vs 33.7%, p< .0001) and transplants (6.8% 
vs 2.0%, p< .0001). After adjusting for complications and comorbidities phosphate 
binder use was associated with 7.7% more inpatient days (IRR = 1.077, p< .0001) and 
a 28% mortality reduction (OR= 0.718, p< .0001). ConClusions: After controlling 
for other variables, CKD patients with hyperphosphatemia receiving PB had lower 
risk of in-hospital mortality and longer LOS compared to patients without a PB. 
Further studies should assess post-hospitalization outcomes as well as variation 
among types of PB.
Urinary/KidnEy disOrdErs – cost studies
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objeCtives: Tunnelled central venous catheters (TCVCs) are frequently used for 
patients requiring urgent vascular access for haemodialysis (HD), whilst they await 
definitive access creation, primarily arteriovenous fistula (AVF). TCVCs are associ-
ated with significant complications notably higher rates of septicaemia which are 
costly to treat. Early cannulation arteriovenous grafts (ecAVGs) are a new alternative 
providing vascular access for HD within 24 hours post implantation. We estimated 
the potential budget impact in a single hospital of replacing TCVCs with ecAVG’s 
for clinically suitable patients while they awaited a functioning AVF. The analysis 
was used to understand the potential financial implications of adopting ecAVGs 
and to inform the decision to conduct a Randomised Controlled Trial (RCT) to study 
the above hypothesis. Methods: A budget impact model was used to estimate 
the total costs to the hospital of the two treatment strategies. Costs of procedures, 
re-interventions and septicaemia were included. Clinical inputs including referral 
delays for treatment and patient acceptability of ecAVG’s, were taken from a 6 month 
observational study conducted at the hospital, internal audits and published litera-
